Summit Therapeutics Inc. (SMMT)

Summit Therapeutics Reports Promising Phase III Results for Lung Cancer Treatment Ivonescimab

Summit Therapeutics (Ticker: SMMT) has made significant strides in the fight against advanced squamous non-small cell lung cancer (NSCLC) with the recent announcement of positive results from its Phas…

Cashu Markets·2 months ago

Summit Therapeutics Reports Major Progress in Lung Cancer Treatment with Ivonescimab Trial Results

Summit Therapeutics has announced significant advancements in its drug development efforts through its collaboration with Akeso. The two companies report promising results from a late-stage trial of i…

Cashu Markets·2 months ago

Summit Therapeutics Set for Significant Quarterly Earnings Report on February 23, 2026

Summit Therapeutics Prepares for Key Quarterly Earnings Report Summit Therapeutics (NASDAQ:SMMT) gears up for its quarterly earnings report set for February 23, 2026. This report is crucial as it will…

Cashu Markets·5 months ago

Summit Therapeutics: Capitalizing on Market Optimism and Growth Opportunities in Biopharma

Summit Therapeutics: Navigating Opportunities Amid Market Optimism Summit Therapeutics, a biopharmaceutical company focused on developing innovative treatments for serious diseases, finds itself in a…

Cashu Markets·8 months ago

Summit Therapeutics Inc.

Recently from Cashu

Summit Therapeutics Reports Promising Phase III Results for Lung Cancer Treatment Ivonescimab

Summit Therapeutics Reports Major Progress in Lung Cancer Treatment with Ivonescimab Trial Results

Summit Therapeutics Set for Significant Quarterly Earnings Report on February 23, 2026

Summit Therapeutics: Capitalizing on Market Optimism and Growth Opportunities in Biopharma

Company Profile